ProfileGDS5678 / 1449984_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 63% 42% 40% 64% 41% 41% 40% 44% 63% 49% 55% 42% 45% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9980242
GSM967853U87-EV human glioblastoma xenograft - Control 23.7522463
GSM967854U87-EV human glioblastoma xenograft - Control 32.9727142
GSM967855U87-EV human glioblastoma xenograft - Control 42.8571140
GSM967856U87-EV human glioblastoma xenograft - Control 53.8138664
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0473341
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0078441
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9177740
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9973444
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7461863
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1542749
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3448155
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9834942
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0418845